Viking Therapeutics Inc is a healthcare service provider... Show more
VKTX moved above its 50-day moving average on June 24, 2025 date and that indicates a change from a downward trend to an upward trend. In of 27 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 72 cases where VKTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VKTX advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on June 17, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on VKTX as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for VKTX turned negative on June 13, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for VKTX crossed bearishly below the 50-day moving average on June 25, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VKTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
VKTX broke above its upper Bollinger Band on June 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VKTX entered a downward trend on June 09, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.592) is normal, around the industry mean (16.539). P/E Ratio (0.000) is within average values for comparable stocks, (59.016). VKTX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.300). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (255.605).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. VKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a company that engages in the development of therapies for metabolic and endocrine disorders
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
GSRRX | 11.27 | N/A | N/A |
Goldman Sachs Rising Dividend Gr R | |||
CFIZX | 14.09 | N/A | N/A |
Columbia Flexible Capital Income Inst | |||
ACWEX | 16.23 | N/A | N/A |
Cavanal Hill World Energy C | |||
FXR | 72.97 | -0.64 | -0.87% |
First Trust Indtls/PrdcrDurbAlphaDEX®ETF | |||
BKMC | 100.64 | -0.98 | -0.97% |
BNY Mellon US Mid Cap Core Equity ETF |
A.I.dvisor indicates that over the last year, VKTX has been loosely correlated with GPCR. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if VKTX jumps, then GPCR could also see price increases.
Ticker / NAME | Correlation To VKTX | 1D Price Change % | ||
---|---|---|---|---|
VKTX | 100% | +0.52% | ||
GPCR - VKTX | 50% Loosely correlated | -2.64% | ||
CRNX - VKTX | 48% Loosely correlated | -1.71% | ||
KRYS - VKTX | 47% Loosely correlated | -0.81% | ||
ALT - VKTX | 47% Loosely correlated | +7.23% | ||
ROIV - VKTX | 45% Loosely correlated | -1.21% | ||
More |